ResultsIQ

ResultsIQ › Latest results › Procter & Gamble Hygiene and Health Care Limited

Procter & Gamble Hygiene and Health Care Limited Q2 FY26 results press release summary

NSE: PGHH · BSE: 500459

Results press release of 6 Nov 2025, summarised by AI from the filing.

PGHH Q2 FY26 sales ₹1150 crore, up 1% versus year ago, PAT ₹210 crores.

Key takeaways

  1. Sales ₹1150 crore, a growth of 1% versus year ago.
  2. PAT ₹210 crores.
  3. Strategy Management executed an integrated growth strategy of a focused product portfolio of daily use categories where performance drives brand choice.
  4. Outlook Management stated the strategy is the right one to deliver sustainable, balanced growth and value creation.
  5. Brands Portfolio includes Whisper, India's leading Feminine Hygiene brand, VICKS, India's No. 1 Health Care brand, and Old Spice.

Original filing on BSE

Procter & Gamble Hygiene and Health Care Limited Q1 FY27 results

As filed: Revenue ₹891 cr (−5% year on year), EBITDA ₹170 cr (−36% year on year), PAT ₹126 cr (−34% year on year), EBITDA margin 19.1% (−931 bps).

The Q1 FY27 score, against the company's own trend, is for premium members.

Earlier results and the share price after them

  • Q4 FY26: Revenue ₹941 cr (−5% year on year), EBITDA ₹218 cr (+4% year on year), PAT ₹153 cr (−2% year on year), EBITDA margin 23.2% (+202 bps). Score 35 of 100, Below trend. Revenue growth was well below the company's own trend; EBITDA growth was in line with it; profit growth was below it. EBITDA margin rose 202 bps year on year. Revenue fell 25% from last quarter. Share price after the results: −10.8% in 28 days (Nifty 500: +0.6%).
  • Q3 FY26: Revenue ₹1,262 cr (+1% year on year), EBITDA ₹402 cr (+8% year on year), PAT ₹301 cr (+12% year on year), EBITDA margin 31.8% (+211 bps). Score 45 of 100, In line with trend. Revenue growth was below the company's own trend; EBITDA and profit growth were in line with it. EBITDA margin rose 211 bps year on year. Share price after the results: −4.7% in 28 days (Nifty 500: +0.1%).
  • Q2 FY26: Revenue ₹1,150 cr (+1% year on year), EBITDA ₹285 cr (−2% year on year), PAT ₹210 cr (−1% year on year), EBITDA margin 24.8% (−77 bps). Score 40 of 100, Below trend. Revenue, EBITDA and profit growth were below the company's own trend. EBITDA margin fell 77 bps year on year. Share price after the results: −6.1% in 29 days (Nifty 500: +0.7%).
  • Q1 FY26: Revenue ₹937 cr (+1% year on year), EBITDA ₹266 cr (+125% year on year), PAT ₹192 cr (+137% year on year), EBITDA margin 28.4% (+1,000 bps). Score 73 of 100, Above trend. Revenue growth was below the company's own trend; EBITDA and profit growth were well above it. EBITDA margin rose 1000 bps year on year. Revenue fell 6% from last quarter. Share price after the results: 0.0% in 30 days (Nifty 500: −2.4%).
  • Q4 FY25: Revenue ₹992 cr (−1% year on year), EBITDA ₹210 cr (−18% year on year), PAT ₹156 cr (+1% year on year), EBITDA margin 21.2% (−448 bps). Score 34 of 100, Below trend. Revenue growth was well below the company's own trend; EBITDA growth was below it; profit growth was in line with it. EBITDA margin fell 448 bps year on year. Revenue fell 21% from last quarter. Share price after the results: −5.7% in 30 days (Nifty 500: +3.1%).
  • Q3 FY25: Revenue ₹1,248 cr (+10% year on year), EBITDA ₹371 cr (+20% year on year), PAT ₹269 cr (+17% year on year), EBITDA margin 29.7% (+237 bps). Score 67 of 100, Above trend. Revenue and profit growth were above the company's own trend; EBITDA growth was in line with it. EBITDA margin rose 237 bps year on year. Profit rose ₹40.0 cr on a year ago, more than the ₹22.0 cr it added the year before.
  • Q2 FY25: Revenue ₹1,135 cr (0% year on year), EBITDA ₹290 cr (+2% year on year), PAT ₹212 cr (0% year on year), EBITDA margin 25.6% (+59 bps). Score 34 of 100, Below trend. EBITDA margin rose 59 bps year on year. Not enough history for a trend yet: scored on growth alone.

Past price moves after results do not indicate future moves. Not a recommendation.

Procter & Gamble Hygiene and Health Care Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.